How should epidermal compounded sterile products be treated with respect to bacteriostatic agents?

Epidermal compounded sterile products should never include bacteriostatic agents due to the potential risks associated with their use in such formulations. Bacteriostatic agents, while effective at inhibiting bacterial growth, can be harmful when applied to areas where skin integrity is compromised, such as in wound care or in patients with open lesions. The introduction of these agents can lead to adverse reactions, increased infection risk, or hinder the healing process.

Instead, the preferred practice for both safety and efficacy is to use sterile products that do not contain bacteriostatic agents for epidermal applications. This is particularly crucial as these products are often intended for direct application to the skin or mucous membranes, where the presence of any potentially harmful additives could pose a significant risk to the patient.